SURVIVAL ANALYSIS OF STAGE I-ITIA BREAST CANCER PATIENTS TREATED WITH MASTECTOMY; 11-YEAR EXPERIENCE IN KING CHULALONGKORN MEMORIAL HOSPITAL
Keywords:
Breast cancer, mastectomy, Stage I-IIIA, Survival analysisAbstract
A retrospective review was performed on 357 stage I-IIIA breast cancer patients who were treated with mastectomy and had been referred to radiation oncology unit, King Chulalongkorn Memorial Hospital, between January 1991 and December 2001. The primary objectives were to report the overall survival and relapse-free survival rates. Survival rates were also stratified by stages, tumor sizes, number of positive axillary lymph nodes and the effect of adjuvant treatment.
The median age in the present study was 49 years. The number of patients were 39, 132, 152 and 34 in stage I, II A, II B and III A respectively. Adjuvant Chemotherapy was given to 247 patients (69.2 %), while adjuvant hormonal therapy was given to 122 patients (34.2 %). Sixty one patients (17.1 %) received both adjuvant chemotherapy and hormonal therapy. Median follow up time was 42.6 months (range 6-136 months).
Five-year overall survival and relapse-free survival rates for the whole group were 72.3% and 58.6%, respectively. The 5-year overall survival rates were 75.2%, 81.0%, 69.0% and 49.8% for stage I, ITA, IIB and IIIA, respectively (P= 0.0001). The corresponding 5-year relapse-free survival rates were 53.9%, 68.1%, 57.5%, and 32.1%, respectively (P=0.0017). Factors significantly affect overall survival rate composed of stages, T-stage, number of positive lymph nodes and regimens of chemotherapy.
Overall, our results of breast cancer treatment in King Chulalongkorn Memorial Hospital were comparable to the previous reports in medical literatures. This study provided base line data of breast cancer treatment results in Thailand, King Chulalongkorn Memorial Hospital.
Downloads
Metrics
References
S. Deerasamue, N. Martin, S. Sontipong, et al. Cancer in Thailand Vol II, 1992-1994.(IARC Scientific Publications No. 145), Lyon, IARC.
Srilung H, Sontipong S, Martin N, et al. Cancer in Thailand 1995-1997 Vol. III: 47-48
Tumor Registry Statistical Report 2000. King Chulalongkorn Memorial Hospital.
Tumor Registry Statistical Report 2001. King Chulalongkorn Memorial Hospital. 3, Cancer in Siriraj 1990-1999.
Cancer Registry. Faculty of Medicine Siriraj Hospital. Mahidol University.
Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-42.
Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351:1451-67.
Lertsanguansinchai P, Lertbutsayanukul C, Chatamra K, etal. Pattern of local-regional recurrence in patient with early breast cancer after mastectomy: an analysis of 357 cases at King Chulalongkorn Memorial Hospital. J Med Assoc Thai 2004; 87: S168-S174
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
American Joint Committee on Cancer. AJCC Cancer staging manual. Philadelphia: Lippincott-Raven, 1997: 171-178.
Saez RA, McGuire WL, Clark GM. Prognostic factors in breast cancer. Semin Surg Oncol 1989; 5: 102-110
Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 71-85.
Fischer B, Anderson S, Tan-Chiu E, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001; 19: 931-942.
Bang SM, Heo DS, Lee KH, et al. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5 -fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Results of a randomized controlled trial. Cancer 2000; 89: 2521-2526.
Levine MN, Bramwell VH, Pritchard KI, etal. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenpausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: 2651- 2658.
The French Adjuvant Study Group. Benefit ofa high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19: 602-611.
Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 The ASEAN Journal of Radiology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Disclosure Forms and Copyright Agreements
All authors listed on the manuscript must complete both the electronic copyright agreement. (in the case of acceptance)
